Review Article| Volume 53, ISSUE 4, P421-430, October 2022

Considerations in the Sickle Cell Patient Undergoing Hip Reconstructive Surgery

Published:September 13, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Orthopedic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Vaishya R.
        • Agarwal A.K.
        • Edomwonyi E.O.
        • et al.
        Musculoskeletal Manifestations of Sickle Cell Disease: A Review.
        Cureus. 2015;
        • Sundd P.
        • Gladwin M.T.
        • Novelli E.M.
        Pathophysiology of Sickle Cell Disease.
        Annu Rev Pathol Mech Dis. 2019; 14
        • Jeong G.K.
        • Ruchelsman D.E.
        • Jazrawi L.M.
        • et al.
        Total hip arthroplasty in sickle cell hemoglobinopathies.
        Am Acad Orthopaedic Surgeons. 2005; 13
        • Kamath A.F.
        • McGraw M.H.
        • Israelite C.L.
        Surgical management of osteonecrosis of the femoral head in patients with sickle cell disease.
        World J Orthopedics. 2015; 6
        • Perfetti D.C.
        • Boylan M.R.
        • Naziri Q.
        • et al.
        Does sickle cell disease increase risk of adverse outcomes following total hip and knee arthroplasty? A nationwide database study.
        J Arthroplasty. 2015; 30: 547-551
        • Farook M.Z.
        • Awogbade M.
        • Somasundaram K.
        • et al.
        Total hip arthroplasty in osteonecrosis secondary to sickle cell disease.
        Int Orthop. 2019; 43
        • Azam M.Q.
        • Sadat-Ali M.
        Quality of Life in Sickle Cell Patients After Cementless Total Hip Arthroplasty.
        J Arthroplasty. 2016; 31
        • Cohen-Rosenblum A.
        • Cui Q.
        Osteonecrosis of the Femoral Head.
        Orthop Clin North Am. 2019; 50: 139-149
        • Korompilias A.v.
        • Lykissas M.G.
        • Beris A.E.
        • et al.
        Vascularised fibular graft in the management of femoral head osteonecrosis: Twenty years later.
        J Bone Joint Surg - Ser B. 2009; 91
        • Hernigou P.
        • Habibi A.
        • Bachir D.
        • et al.
        The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease.
        J Bone Joint Surg - Ser A. 2006; 88
        • Issa K.
        • Naziri Q.
        • Maheshwari A.v.
        • et al.
        Excellent results and minimal complications of total hip arthroplasty in sickle cell hemoglobinopathy at mid-term follow-up using cementless prosthetic components.
        J Arthroplasty. 2013; 28
        • Patel Y.
        • Szczech B.
        • Patel S.
        • et al.
        Management strategies for total hip arthroplasty in sickle cell patients.
        J Long-Term Effects Med Implants. 2014; 24
        • Hernigou P.
        • Bachir D.
        • Galacteros F.
        The natural history of symptomatic osteonecrosis in adults with sickle-cell disease.
        J Bone Joint Surg - Ser A. 2003; 85
        • Oyedeji C.I.
        • Welsby I.J.
        Perioperative Man Age Ment of Sickle Cell Dis Ease | 405 Optimizing Man Age Ment of Sickle Cell Dis Ease in Patients under Go Ing Sur Gery.
        (Available at:)
        • Vichinsky E.P.
        • Neumayr L.D.
        • Haberkern C.
        • et al.
        The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the national sickle cell surgery study group.
        Am J Hematol. 1999; 62 (199911)62:3<129::AID-AJH1>3.0.CO;2
        • Hernigou P.
        • Zilber S.
        • Filippini P.
        • et al.
        Total THA in adult osteonecrosis related to sickle cell disease.
        Clin Orthopaedics Relat Res. 2008; 466
        • Khurmi N.
        • Gorlin A.
        • Misra L.
        Perioperative considerations for patients with sickle cell disease: a narrative review.
        Can J Anesth. 2017; 64
        • Vichinsky E.P.
        • Earles A.
        • Johnson R.A.
        • et al.
        Alloimmunization in Sickle Cell Anemia and Transfusion of Racially Unmatched Blood.
        N Engl J Med. 1990; 322
        • Vichinsky E.P.
        • Haberkern C.M.
        • Neumayr L.
        • et al.
        A Comparison of Conservative and Aggressive Transfusion Regimens in the Perioperative Management of Sickle Cell Disease.
        N Engl J Med. 1995; 333
        • Ould Amar K.
        • Rouvillain J.L.
        • Loko G.
        Perioperative transfusion management in patients with sickle cell anaemia undergoing a total hip arthroplasty. Is there a role of red-cell exchange transfusion? A retrospective study in the CHU of Fort-de-France Martinique.
        Transfus Clinique Biologique. 2013; 20
        • Ilyas I.
        • Alrumaih H.A.
        • Rabbani S.
        Noncemented Total Hip Arthroplasty in Sickle-Cell Disease: Long-Term Results.
        J Arthroplasty. 2018; 33
        • Hickman J.M.
        • Lachiewicz P.F.
        Results and complications of total hip arthroplasties in patients with sickle-cell hemoglobinopathies: Role of cementless components.
        J Arthroplasty. 1997; 12
        • Kalacy A.
        • Ozkan C.
        • Togrul E.
        Revision hip arthroplasty in sickle cell disease.
        Ann Saudi Med. 2007; 27
        • Acurio M.T.
        • Friedman R.J.
        Hip arthroplasty in patients with sickle-cell haemoglobinopathy.
        J Bone Joint Surg - Ser B. 1992; 74
        • Hernigou P.
        • Housset V.
        • Pariat J.
        • et al.
        Total hip arthroplasty for sickle cell osteonecrosis: guidelines for perioperative management.
        EFORT Open Rev. 2020; 5
        • Adjepong K.O.
        • Otegbeye F.
        • Adjepong Y.A.
        Perioperative management of sickle cell disease.
        Mediterr J Hematol Infect Dis. 2018; 10
        • Okpala I.
        • Tawil A.
        Management of pain in sickle-cell disease.
        J R Soc Med. 2002; 95
        • Styles L.A.
        • Vichinsky E.P.
        Core decompression in avascular necrosis of the hip in sickle-cell disease.
        Am J Hematol. 1996; 52 (199606)52:2<103::AID-AJH6>3.0.CO;2-Y
        • Hsu J.E.
        • Wihbey T.
        • Shah R.P.
        • et al.
        Prophylactic decompression and bone grafting for small asymptomatic osteonecrotic lesions of the femoral head.
        HIP Int. 2011; 21
        • Moran M.C.
        Osteonecrosis of the hip in sickle cell hemoglobinopathy.
        Am J Orthop. 1995; 24
        • AlOmran A.S.
        Choice of implant in total hip arthroplasty for sickle cell disease patients.
        Eur Orthopaedics Traumatol. 2010; 1
        • Gulati Y.
        • Sharma M.
        • Bharti B.
        • et al.
        Short term results of cementless total hip arthroplasty in sicklers.
        Indian J Orthopaedics. 2015; 49
        • Fassihi S.C.
        • Lee R.
        • Quan T.
        • et al.
        Total Hip Arthroplasty in Patients With Sickle Cell Disease: A Comprehensive Systematic Review.
        J Arthroplasty. 2020; 35
        • Kenanidis E.
        • Kapriniotis K.
        • AnagnOstis P.
        • et al.
        Total hip arthroplasty in sickle cell disease: A systematic review.
        EFORT Open Rev. 2020; 5: 180-188
        • Clarke H.J.
        • Jinnah R.H.
        • Brooker A.F.
        • et al.
        Total replacement of the hip for avascular necrosis in sickle cell disease.
        J Bone Joint Surg - Ser B. 1989; 71
        • Severyns M.
        • Gayet L.E.
        Aseptic osteonecrosis of the femoral head in patients with sickle cell anemia.
        Morphologie. 2021; : 105
        • Gu A.
        • Agarwal A.R.
        • Fassihi S.C.
        • et al.
        Impact of sickle cell disease on postoperative outcomes following total hip arthroplasty.
        HIP Int. 2021;
        • Neonato M.G.
        • Guilloud-Bataille M.
        • Beauvais P.
        • et al.
        Acute clinical events in 299 homozygous sickle cell patients living in france.
        Eur J Haematol. 2000; 65
        • Espehaug B.
        • Engesaeter L.B.
        • Vollset S.E.
        • et al.
        Antibiotic prophylaxis in total hip arthroplasty.
        J Bone Joint Surg - Ser B. 1997; 79